ArticleNature biotechnology2011
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.Archives of dermatological research · 2022Pooled it
- A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.Frontiers in immunology · 2020Pooled it
- Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2019Pooled it
- Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2016Pooled it
- Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.PloS one · 2012Trial
- Article
- Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium Net.BMJ open gastroenterology · 2026Article
- Risankizumab redefines Crohn's treatment after ustekinumab failure.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Ustekinumab-associated morphoea: systematic review of the literature and a real-world case.Drugs in context · 2026Review
- Combination therapy with spesolimab and apremilast for refractory generalized pustular psoriasis: a case report.Frontiers in medicine · 2025Article
- Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.Journal of clinical medicine · 2024Review
- Polymorphism of IL-12/IL-23 axis is associated with coronary heart disease.Journal of cellular and molecular medicine · 2024Article
- Interleukin inhibitors and the associated risk of candidiasis.Frontiers in immunology · 2024Review
- Intestinal Behcet's Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents.International journal of molecular sciences · 2023Review
- Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab.ImmunoHorizons · 2023Article
- Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.Frontiers in immunology · 2023Review
- Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.Experimental dermatology · 2022Article
- Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.Gastroenterology & hepatology · 2022Article
- Probing the binding of interleukin-23 to individual receptor components and the IL-23 heteromeric receptor complex in living cells using NanoBRET.Cell chemical biology · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical and clinical studies conducted in the mid-1990s reported strong association and causality between the T-cell helper (T(H)) 1 inductor cytokine interleukin (IL)-12 and numerous immune-mediated disorders, which spurred the development of therapeutic agents targeting IL-12 function. One of the first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 subunit of IL-12. Subsequent to the generation of ustekinumab, it was discovered that IL-23 also contains the p40 subunit. Thus, although ustekinumab was designed to target IL-12, it also modulates IL-23, a cytokine important to the development and/or maintenance of T(H)17 cells. Clinical observations established that IL-12/23p40 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease. The molecular and cellular evaluations conducted in ustekinumab clinical programs have provided numerous insights into the pathologic processes of these disorders, illustrating how a novel molecular entity can contribute to our understanding of disease. The individual contributions of these cytokines to specific pathologies require investigation and clinical evaluation of the role of IL-12- and IL-23-specific inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.